Zobrazeno 1 - 10
of 187
pro vyhledávání: '"59"'
Autor:
Felix Stader, Thierry Buclin, Monia Guidi, Susana Alves Saldanha, Matthias Cavassini, Laurent A. Decosterd, Catia Marzolini, Perrine Courlet, Marcel Stoeckle, Chantal Csajka
Publikováno v:
Clinical Pharmacokinetics
Clinical pharmacokinetics, vol. 59, no. 8, pp. 1037-1048
Clinical pharmacokinetics, vol. 59, no. 8, pp. 1037-1048
Background People living with HIV (PLWH) are aging and experience age-related physiological changes and comorbidities. Atorvastatin is a widely prescribed lipid-lowering agent metabolized by cytochrome P450 (CYP) 3A4, whose hepatocyte uptake is facil
Autor:
Luciana Kikuchi, Alice M. Isejima, Paulo M. Hoff, Marcelo Queiroz, Leonardo Gomes da Fonseca, Maria Ignez Braghiroli, Joao Glasberg, Christian Kappeler, Luiz Antonio Senna Leite, Daniela R. Nebuloni, Giovanni M. Bariani, Rachel P. Riechelmann, Thomas Giollo Rivelli
Publikováno v:
The Oncologist. 24:1180-1187
Background Regorafenib is a multikinase inhibitor with antiangiogenic effects that improves overall survival (OS) in metastatic colorectal cancer (mCRC) after failure of standard therapies. We investigated the efficacy and safety of regorafenib in an
Autor:
Marlinde L. van den Boogaard, Helen N. Pemberton, Jennifer R. Tall, Sabine Hartlieb, Helen E. Bryant, James Campbell, Barbara Martins da Costa, Sally L. George, Christopher J. Lord, Federica Lorenzi, Louis Chesler, Umut H. Toprak, David A. King, Jan J. Molenaar, Karen Barker, M. Emmy M. Dolman, Frank Westermann
Publikováno v:
EBioMedicine, Vol 59, Iss, Pp 102971-(2020)
EBioMedicine
EBioMedicine, 59. Elsevier BV
EBioMedicine
EBioMedicine, 59. Elsevier BV
Background In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup. Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research. Methods To evaluate the impact o
Autor:
Daria S. Chulpanova, Ekaterina Garanina, Svetlana F. Khaiboullina, Marina O. Gomzikova, Elvira R. Akhmetzyanova, Svetlana S. Arkhipova, Valeriya V. Solovyeva, Victoria James, Albert A. Rizvanov, Leysan G. Tazetdinova
Publikováno v:
Bioengineering
Volume 7
Issue 2
Bioengineering, Vol 7, Iss 59, p 59 (2020)
Volume 7
Issue 2
Bioengineering, Vol 7, Iss 59, p 59 (2020)
High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal cell carcinoma and metastatic melanoma. However, systemic administration of high doses of IL2 can be toxic, causing capillary leakage syndrome and stimulating
Autor:
Sophie E. M. Veldhuijzen van Zanten, Otto S. Hoekstra, Esther Hulleman, Pieter Wesseling, A. Charlotte P. Sewing, Marianna Bugiani, Gertjan J.L. Kaspers, Michaël H. Meel, Dannis G. van Vuurden, Arthur van Lingen
Publikováno v:
Journal of Nuclear Medicine, 59(4), 612-615. Society of Nuclear Medicine Inc.
Veldhuijzen van Zanten, S E M, Sewing, A C P, van Lingen, A, Hoekstra, O S, Wesseling, P, Meel, M H, van Vuurden, D G, Kaspers, G J L, Hulleman, E & Bugiani, M 2018, ' Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma ', Journal of Nuclear Medicine, vol. 59, no. 4, pp. 612-615 . https://doi.org/10.2967/jnumed.117.197897
Journal of nuclear medicine, 59(4), 612-615. Society of Nuclear Medicine Inc.
Veldhuijzen van Zanten, S E M, Sewing, A C P, van Lingen, A, Hoekstra, O S, Wesseling, P, Meel, M H, van Vuurden, D G, Kaspers, G J L, Hulleman, E & Bugiani, M 2018, ' Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma ', Journal of Nuclear Medicine, vol. 59, no. 4, pp. 612-615 . https://doi.org/10.2967/jnumed.117.197897
Journal of nuclear medicine, 59(4), 612-615. Society of Nuclear Medicine Inc.
Inadequate tumor uptake of the vascular endothelial growth factor (VEGF) antibody bevacizumab could explain lack of effect in diffuse intrinsic pontine glioma (DIPG). Methods: By combining data from a positron emission tomography (PET) imaging study
Autor:
Roberta Rudà, Bruno Daniele, Giuseppe Lombardi, Stefano Indraccolo, Luisa Bellu, Marina Paola Gardiman, Alba A. Brandes, Riccardo Soffietti, Miriam Farina, Marina Faedi, Marica Eoli, Giovanna Magni, Gian Luca De Salvo, Ivan Lolli, Andrea Pace, Francesco Pasqualetti, Vittorina Zagonel, Ardi Pambuku, Simona Rizzato
Summary Background Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases. We aimed to as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44780d7790dc44790605ec374837c95
http://hdl.handle.net/2318/1690639
http://hdl.handle.net/2318/1690639
Autor:
Samuel Sevestre, Vincent Boudousq, Pierre Le Fur, Joanna Koch, Alexandre Pichard, Jean-Pierre Pouget, Pierre-Olivier Kotzki, Riad Ladjohounlou, Jane K. Sosabowski, Alfred Morgenstern, Nicolas Chouin, Julie Foster, Catherine Lozza, Emmanuel Deshayes, Isabelle Navarro-Teulon, Roxana Kashani, Marta Jarlier, Frank Bruchertseifer
Publikováno v:
Journal of Nuclear Medicine
Journal of Nuclear Medicine, Society of Nuclear Medicine, 2018, 59 (8), pp.1234-1242. ⟨10.2967/jnumed.118.208611⟩
Journal of Nuclear Medicine, 2018, 59 (8), pp.1234-1242. ⟨10.2967/jnumed.118.208611⟩
Journal of Nuclear Medicine, Society of Nuclear Medicine, 2018, 59 (8), pp.1234-1242. ⟨10.2967/jnumed.118.208611⟩
Journal of Nuclear Medicine, 2018, 59 (8), pp.1234-1242. ⟨10.2967/jnumed.118.208611⟩
International audience; We have developed the 16F12 mouse monoclonal antibody (mAb), which targets the M ¨ ullerian-inhibiting substance receptor, type II (MISRII), expressed by ovarian tumors. Here, we assessed in preclinical models the possibility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67631460c2972a10500b351256f73dca
https://www.hal.inserm.fr/inserm-01885063v2/document
https://www.hal.inserm.fr/inserm-01885063v2/document
Autor:
Niels J. Sijbrandi, Joey A. Muns, Veronica Montserrat, Karlijn Codee-van der Schilden, Oene Zwaagstra, Hendrik Jan Houthoff, Guus A.M.S. van Dongen, Eugen Merkul
Publikováno v:
Journal of Nuclear Medicine, 59(7), 1146-1151. Society of Nuclear Medicine Inc.
Muns, J A, Montserrat, V, Houthoff, H J, Codée-Van Der Schilden, K, Zwaagstra, O, Sijbrandi, N J, Merkul, E & Van Dongen, G A M S 2018, ' In vivo characterization of platinum (II)-based linker technology for the development of antibody-drug conjugates : Taking advantage of dual labeling with 195m Pt and 89 Zr ', Journal of Nuclear Medicine, vol. 59, no. 7, pp. 1146-1151 . https://doi.org/10.2967/jnumed.117.206672
Muns, J A, Montserrat, V, Houthoff, H J, Codée-Van Der Schilden, K, Zwaagstra, O, Sijbrandi, N J, Merkul, E & Van Dongen, G A M S 2018, ' In vivo characterization of platinum (II)-based linker technology for the development of antibody-drug conjugates : Taking advantage of dual labeling with 195m Pt and 89 Zr ', Journal of Nuclear Medicine, vol. 59, no. 7, pp. 1146-1151 . https://doi.org/10.2967/jnumed.117.206672
Linker instability and impaired tumor targeting can affect the tolerability and efficacy of antibody-drug conjugates (ADCs). To improve these ADC characteristics, we recently described the use of a metal-organic linker, [ethylenediamineplatinum(II)]2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3406f21b858decb6ae684290c161efbc
https://research.vumc.nl/en/publications/b9ab39cb-14e7-4615-be59-042bb4e34442
https://research.vumc.nl/en/publications/b9ab39cb-14e7-4615-be59-042bb4e34442
Autor:
Anna Maria Storniolo, Aditya Bardia, Cesar A. Santa-Maria, Vered Stearns, Claire F. Snyder, Antonio C. Wolff, Stacie Jeter, Anne Nguyen, Shannon Slater, Daniel F. Hayes, John H. Fetting, Katie Quinlan, Robert S. Miller, Roisin M. Connolly, Nora Lynn Henry, Gary L. Rosner, Jane Zorzi, Amanda L. Blackford
Publikováno v:
Breast cancer research and treatment. 171(1)
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced
Autor:
C. Rory Goodwin, Yunqing Li, Hernando Lopez, Olutobi Oyinlade, Alessandro Olivi, Harsharan Kaur, Prakash Rath, Sandra Ho, Bachchu Lal, A. Karim Ahmed, Xin Zhou, Shuli Xia, Salman Mughal
Objectives Receptor tyrosine kinases (RTK), such as c-Met and epidermal growth factor receptor (EGFR), are implicated in the malignant progression of glioblastoma. Studies show that RTK systems can co-modulate distinct and overlapping oncogenic downs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc51e83dafcb5c823ff913bb4c121a8
http://hdl.handle.net/10807/206763
http://hdl.handle.net/10807/206763